The Cochlear Ltd (ASX: COH) share price has been on a downward spiral since the beginning of 2025, leaving investors wondering if it's time to add this healthcare stock to their watchlist. But is this a buying opportunity or a sign of trouble? Let's delve into the reasons why investors might be drawn to healthcare shares and whether COH is a good fit.
The Appeal of Healthcare Shares
Healthcare is a sector that often flies under the radar, but it's a powerful force in the investment world. Here's why:
Sticky Revenue
Healthcare spending is essential, and it's one of the last areas people cut back on during economic downturns. This is what we call 'sticky' revenue, and it's a key differentiator for healthcare companies. During the Global Financial Crisis (GFC), healthcare was the best-performing sector, proving its resilience. This stability is a rare commodity in today's volatile markets, making healthcare a reliable investment choice.
Growth Potential
The healthcare sector is set to boom, with global healthcare spending projected to grow significantly, especially in the US, which accounts for over 40% of the global total. Estimates suggest a 7% annual growth rate from 2022 to 2027, reaching a staggering US$819 billion. Within this sector, sub-sectors like healthcare IT, data solutions, and software-as-a-service (SaaS) are forecast to grow at an impressive rate of over 15% per year from 2024 to 2030. This growth potential is a major attraction for investors seeking long-term gains.
Ethical Investing
The rise of ethical and sustainable investing is another factor in the healthcare sector's favor. A Morgan Stanley survey revealed that over half of investors plan to increase their allocation to sustainable investments in 2024. With a growing interest in ethical practices, healthcare companies, which provide essential public services, are well-positioned to attract new capital and investors. This trend is likely to continue, making healthcare a key focus for socially conscious investors.
COH Share Price Analysis
Cochlear Ltd, a global leader in hearing technology, has seen its share price decline by 52.2% since the start of 2025. While this might seem like a red flag, it's essential to consider the broader context. The current price-sales ratio of 3.65x is below its 5-year average of 9.18x, suggesting that the shares are trading at a lower valuation. This could indicate that the price has fallen due to external factors or that sales have increased, which is a positive sign.
However, investment decisions should not be based solely on one metric. The Rask websites offer valuable online investing courses and free valuation spreadsheets, including Discounted Cash Flow (DCF) and Dividend Discount Models (DDM), which can provide a more comprehensive analysis of the COH share price. These models can help investors make more informed decisions by considering the company's future cash flows and dividend payments.
In conclusion, while the COH share price has taken a hit recently, the healthcare sector's resilience, growth potential, and alignment with ethical investing trends make it an attractive investment opportunity. As with any investment, thorough research and a long-term perspective are key. Investors should consider the broader context and use various valuation techniques to make informed decisions. Healthcare shares, like COH, could be a solid addition to a well-diversified portfolio.
